home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9408c.zip
/
M9480569.TXT
< prev
next >
Wrap
Text File
|
1994-08-20
|
2KB
|
33 lines
Document 0569
DOCN M9480569
TI Does intravenous immune globulin have a role in HIV-infected patients?
DT 9410
AU Yap PL; Edinburgh & South East Scotland Blood Transfusion Service, UK.
SO Clin Exp Immunol. 1994 Jul;97 Suppl 1:59-67. Unique Identifier :
AIDSLINE MED/94306770
AB The main immunological abnormality in human immunodeficiency virus
(HIV)-infected patients, and particularly those with the acquired immune
deficiency syndrome (AIDS), is a deficiency in cellular immunity.
However, symptomatic HIV-infected children also have evidence of
deficiency of specific antibody synthesis, and intravenous immune
globulin (IVIG) preparations in doses of 0.2-0.4 g/kg every 2-4 weeks
have been shown to reduce the incidence of respiratory infections. IVIG
therapy may also reduce the mortality and incidence of bacterial
infections in adults but further studies are required. In addition,
high-dose IVIG therapy (1-2 g/kg over 2-5 days) produces increased
platelet counts in patients with idiopathic thrombocytopenic purpura
(ITP) associated with HIV infection. Finally, IVIG therapy may have a
role in HIV-infected patients suffering from severe parvovirus B19 or
measles infection, or in patients suffering from autoimmune disorders
where high-dose IVIG therapy has been shown to be efficacious.
DE Adult AIDS-Related Opportunistic Infections/PREVENTION & CONTROL/
THERAPY Child Clinical Trials Human HIV
Infections/COMPLICATIONS/IMMUNOLOGY/*THERAPY Immunoglobulins,
Intravenous/*THERAPEUTIC USE Purpura, Thrombocytopenic,
Idiopathic/COMPLICATIONS/THERAPY JOURNAL ARTICLE REVIEW REVIEW,
TUTORIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).